DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Lucatumumab
Lucatumumab
Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
Modifications to the Harmonized Tariff Schedule of the United States to Implement Changes to the Pharmaceutical Appendix
New Biological Therapies: Introduction to the Basis of the Risk of Infection
B-Cell Targets to Treat Antibody-Mediated Rejection In
Highlights from the Pan Pacific Lymphoma Conference
An Analysis of Toxicity and Response Outcomes from Dose
Monoclonal Antibody-Based Therapy As a New Treatment Strategy in Multiple Myeloma
GRP78-Directed Immunotherapy in Relapsed Or Refractory Multiple Myeloma - Results from a Phase 1 Trial with the Monoclonal Immunoglobulin M Antibody PAT-SM6
Monoclonal Antibody Therapy for Classical Hodgkin Lymphoma
Ep 3178848 A1
(INN) for Biological and Biotechnological Substances
Ep 3321281 A1
Co-Stimulatory Versus Cell Death Aspects of Agonistic CD40 Monoclonal Antibody Selicrelumab in Chronic Lymphocytic Leukemia
Monoclonal Antibodies for the Treatment of Multiple Myeloma: an Update
Multiple Myeloma Therapies What Lies in the Future?
CLL June 18 2014 Slides
INN Working Document 05.179 Update 2011
IUPAC Glossary of Terms Used in Immunotoxicology (IUPAC Recommendations 2012)*
Top View
Recent Biotherapies and Infections
Multiple Myeloma in the Era of Novel Agents
(INN) for Biological and Biotechnological Substances
Rapid Progress in Immunotherapies for Multiple Myeloma: an Updated Comprehensive Review
Collaborative Practice in the Management of Patients with Cancer Management of Multiple Myeloma Patients Treated with Immunotherapy Program Chair
Ep 2739649 B1
Chronic Lymphocytic Leukemia: 2013 Update on Diagnosis, Risk Stratification and Treatment Michael Hallek*
N° 18380 A61k 31/5377 (2018.01) A61p 35/02 (2018.01)
Investigational Monoclonal Antibodies in the Treatment of Multiple Myeloma: a Systematic Review of Agents Under Clinical Development
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
Target Therapy in Hematological Malignancies Safa Shukry, Fadhel Hariri and Abdul Wahab Al-Nehmi
United States Patent $835 a 88: As: Inhibitor 1-((R)-3-(4-Amino-3-(4
New Antibody Approaches to Lymphoma Therapy Tejas Suresh1, Lisa X Lee1, Jitesh Joshi1 and Stefan K Barta2*
Monoclonal Antibodies in the Treatment of Multiple Myeloma: Current Status and Future Perspectives
Pharmaabkommen A1 E
Biotechnology Presented by America’S Biopharmaceutical Research Companies
Immune Therapy in Multiple Myeloma
Pharmaceutical Products and Chemical Intermediates, Fourth Review: Advice Concerning the Addition of Certain Products to the Pharmaceutical Appendix to the HTS
Com(2010)0397
Presentación De Powerpoint
Immunotherapy in Chronic Lymphocytic Leukaemia (CLL)
(12) United States Patent (10) Patent No.: US 9,345,770 B2 Storkus Et Al
The Honorable Shara Aranoff Chairman United States International Trade Commission 500 E Street, S.W. Washington, DC 20436 Dear C
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
International Journal of Current Advanced Research
Activated B-Cell
Immune-Checkpoint Inhibitors in B-Cell Lymphoma
Us 2019 / 0202839 A1
Protein-Polymer-Drug Conjugates Protein-Polymer-Wirkstoffkonjugate Conjugués De Médicament-Protéine-Polymère
Cancer PRESENTEDBYAMERICA ’ SBIOPHARMACEUTICALRESEARCHCOMPANIES Nearly 900 Medicines and Vaccines in Testing Offer Hope in the Fight Against Cancer
(INN) for Biological and Biotechnological Substances
University of Groningen TNF Receptor Superfamily-Based Targeted Cancer
Medicines & Vaccines in Development for Cancer
Monoclonal Antibody Triplets for First Relapse
A Circulating Antibody Panel for Pretransplant Prediction of FSGS Recurrence After Kidney Transplantation Marianne Delville Et Al
Ep 3088005 A1
Assessment of the Evolution of Cancer Treatment Therapies
Oncology Drugs in the Pipeline
Multiple Myeloma Conversation”
Timepoint 1 Geting Assembly Complexes (Attacs) for Selectively Activating De¬ Sired Immune Cells in the Tumor Microenvironment
BHS Guidelines for the Treatment of Chronic Lymphocytic Leukaemia
Review Article Monoclonal Antibody Therapies in Multiple Myeloma: a Challenge to Develop Novel Targets
Immunotherapy for B-Cell Lymphoma: Current Status and Prospective Advances
The Evolution in the Treatment of Multiple Myeloma Towards Targeted Magnetic Molecularly Imprinted Nanomedicines Edgar Pérez-Herrero
INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri
(12) Patent Application Publication (10) Pub. No.: US 2015/0374790 A1 Liu Et Al
Signaling the End of Chronic Lymphocytic Leukemia: New Frontline Treatment Strategies
Monoclonal Antibodies for the Treatment of Multiple Myeloma: an Update
Current Antibody-Based Therapies for the Treatment of Multiple Myeloma